About Embla Medical

Sveinn Sölvason, President and CEO, comments:

"Sales in Q2 2025 amounted to USD 232 million and reported growth was 7% of which 5% was organic.

Growth was strong in our Prosthetics & Neuro Orthotics segment, mainly driven by the continued strong momentum in EMEA supported by solid contribution from our recently launched innovation.

The EBITDA margin was strong at 21% in Q2 2025. The margin benefited positively from strong sales in Prosthetics & Neuro Orthotics, solid efficiency in manufacturing, and continued strong cost control in SG&A."

Embla will host a conference call on July 22, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST. Please visit our Investor Relations section for further information.

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.